The University of Montpellier has secured new funding for its NANOREMEDI project (
)
Theproject Functional Nano-Scaffolds for Regenerative Medicine, also known as NANOREMEDI, led by Gilles Subra, a professor at the Faculty of Pharmacy, and Cécile Echalier, a faculty member specializing in chemistry of biomaterials at IBMM, with the participation of Danièle Noël’s team at IRMB, has secured, €565,000 in funding under the Marie Skłodowska-Curie Actions Doctoral Network for the training and research of doctoral students at the University of Montpellier.
The NANOREMEDI Project at a Glance
NANOREMEDI, which officially launched on September1, 2022, for a duration of four years, is a Marie Skłodowska-Curie Actions Doctoral Network project led by a consortium of six universities in Europe. The main objective is to train 13 doctoral researchers the field of peptides and nanomaterials. Each researcher will be co-supervised by two universities and will spend the majority of their time at the university that recruits them, nine months at the second university, and three months with an industrial partner. In addition, these doctoral researchers from cross-disciplinary and interdisciplinary training and will participate in international workshops organized by NANOREMEDI partners. The University of Montpellier will therefore recruit two for this project in joint supervision with the University of Milan (Italy) and IC Nanogune (San Sebastian, Spain) and will host two others for a period of 9 months each, also in joint supervision with the University of Milan and the Hebrew University of Jerusalem.
From a scientific perspective, the project aims to improve human health by addressing three major challenges:
- The development of vascular grafts to replace damaged arteries,
- The development of stem cell-based therapies for bone and cartilage repair,
- The development of strategies to promote implant integration and prevent bacterial contamination.
Funding for the IBM and the IRMB at the University of Montpellier
In collaboration with the University of Montpellier and five other universities: the University of Milan (Department of Pharmaceutical Sciences), the Universitat Politècnica de Catalunya (Barcelona Tech, Department of Chemical Engineering), The Hebrew University of Jerusalem (Institute of Chemistry), the University of Pavia (Department of Drug Sciences), IC NANOGUNE (“Self-Assembly” Group, San Sebastian), as well as 11 industrial partners, including two French companies (Lynxter and Genepep), are leading the NANOREMEDI project, which has received total funding of €3.4 million.
As a result,UM €565,000. This provides the IBMM and the IRMB with the resources to fund consumables and equipment to support doctoral research and organize workshops. This same Marie Skłodowska-Curie Actions Doctoral Network funding enables the implementation of doctoral programs in partnership with universities and companies across various sectors throughout Europe to train highly qualified doctoral students, stimulate their creativity, strengthen their capacity for innovation, and ensure their long-term employability in Europe.
Practical information:
The NANOREMEDI project in detail: https://www.nanoremedi.eu/